Daejeon, South Korea

Chung-Ryeol Kim


Average Co-Inventor Count = 9.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 1997

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations of Chung-Ryeol Kim in HIV Research

Introduction

Chung-Ryeol Kim is a notable inventor based in Daejeon, South Korea. He has made significant contributions to the field of medical research, particularly in the development of compounds aimed at combating HIV. With a total of 2 patents to his name, his work is pivotal in the ongoing fight against this virus.

Latest Patents

Chung-Ryeol Kim's latest patents include innovative compounds that serve as irreversible HIV protease inhibitors. These compounds are designed to inhibit the activity of the human immunodeficiency virus (HIV) protease, which is crucial for the virus's replication. The patents detail a process for the preparation of these compounds and their use in compositions for the prevention or treatment of AIDS caused by HIV infection. The compounds are characterized by a specific formula, where R¹ can be an aromatic group, a nitrogen-containing aromatic group, or various alkyl and alkoxy groups that may be substituted with aromatic or nitrogen-containing groups.

Career Highlights

Chung-Ryeol Kim is associated with LG Chemical Ltd., a leading company in the chemical industry. His work at this organization has allowed him to focus on innovative solutions in the pharmaceutical sector, particularly in the development of antiviral agents.

Collaborations

Chung-Ryeol Kim has collaborated with notable colleagues such as Nakyen Choy and Hoil Choi. These collaborations have further enhanced the research and development of effective treatments for HIV.

Conclusion

Chung-Ryeol Kim's contributions to HIV research through his innovative patents highlight the importance of scientific advancements in combating viral infections. His work continues to inspire further research in the field of virology and pharmaceutical development.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…